Valneva (NASDAQ:VALN) Stock Price Down 6.6%

Valneva SE (NASDAQ:VALN - Get Free Report)'s share price was down 6.6% during trading on Tuesday . The company traded as low as $8.04 and last traded at $8.04. Approximately 2,765 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 9,495 shares. The stock had previously closed at $8.61.

Analyst Ratings Changes

A number of equities analysts have recently commented on VALN shares. Guggenheim dropped their price objective on Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Friday, March 22nd. HC Wainwright restated a "buy" rating and set a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st.

Valneva Stock Down 5.9 %

The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. The stock has a market capitalization of $562.63 million, a P/E ratio of -5.09 and a beta of 2.25. The firm has a 50 day moving average of $7.65 and a 200-day moving average of $9.82.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG acquired a new stake in Valneva during the second quarter valued at approximately $31,000. Jane Street Group LLC boosted its holdings in Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock valued at $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Valneva during the first quarter valued at approximately $858,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.